[1] 高艳,杨秋杰.临床路径应用于肿瘤化疗的Meta分析[J].现代医学,2013,4(6):393-397.
[2] 孙蕊,朱琰,刘玉琴.肿瘤靶向治疗药物载体的研究进展[J].药学研究,2014,33(5):249-252.
[3] YUE X,DAI Z.Recent advances in liposomal nanohybrid cerasomes as promising drug nanocarriers[J].Adv Colloid Interface Sci,2014,207:32-42.
[4] GUO S T,HUANG L.Nanoparticles containing insoluble drug for cancer therapy[J].Biotechnol Adv,2014,32:778-788.
[5] WINTER O,MOSER K,MOHR E,et al.Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow[J].Blood,2010,116:1867-1875.
[6] MENTER D G,TUCKER S C,KOPETZ S,et al.Platelets and cancer:a casual or causal relationship:revisited[J].Cancer Metastasis Rev,2014,33:231-269.
[7] GHUMLAS A A,GADER A G M A.The blood platelet:an intriguing cell [J].Appl Hematol,2013,4:1-12.
[8] KAUSHANSKY K.The molecular mechanisms that control thrombopoiesis[J].Clin Invest,2005,115:3339-3347.
[9] DEUTSCH V R,TOMER A.Megakaryocyte development and platelet production[J].Haematol,2006,134:453-466.
[10] BECKER R C,SMYTH S.The evolution of platelet-directed pharmacotherapy[J].Thromb Haemost,2009,7:266-271.
[11] 陈新伟,李启明.血小板生成机制与巨核细胞成熟、凋亡[J].重庆医学,2010,39(7):878-881.
[12] WALSH T G,METHAROM P,BERNDT M C.The functional role of platelets in the regulation of angiogenesis[J/OL.].http://informahhealthcare.com/plt[2014-05-15].
[13] WONG A K T.Platelet biology:the role of shear[J].Expert Rev Hematol,2013,6:205-212.
[14] NUGENT D,MCMILLAN R,NICHOL J L,et al.Pathogenesis of chronic immune thrombocytopenia:Increased platelet destruction and/or decreased platelet production[J].Haematol,2009,146:585-596.
[15] TSIARA S,COOPER N.Eltrombopag for the treatment of chronic immune thrombocytopenia[J].Clin Investig,2011,1:295-303.
[16] GOUBRAN H A,STAKIW J,RADOSEVIC M,et al.Platelets effects on tumor growth[J].Seminars in Oncology,2014,41(3):359-369.
[17] BAMBACE N,HOLMES C.The platelet contribution to cancer progression[J].Thromb Haemost,2011,9:237-249.
[18] WHITE J G.Platelets are covercytes,not phagocytes:uptake of bacteria involves channels of the open canalicular system[J].Platelets,2005,16:121-131.
[19] DEB S,PATRA H K,LAHIRI P,et al.Multistability in platelets and their response to gold nanoparticles[J].Nanomedicine,2011,7:376-384.
[20] SARKAR S,ALAM M A,SHAW J,et al.Drug delivery using platelet cancer cell interaction[J].Pharm Res,2013,30:2785-2794.
[21] BUCKLEY M F,JAMES J W,BROWN D E.A novel approach to the assessment of variations in the human platelet count[J].Thromb Haemost,2000,83:480-484.
[22] DAVIES A,LEWIS D J,WATSON S P,et al.pH-controlled delivery of luminescent europium coated nanoparticles into platelets[J].PNSA,2012,109(6):1862-1867.
[23] TAYLOR H L,WHITLEY P,HEATON A.A historical perspective on platelet radiolabeling techniques[J].Transfusion,2006,46:53-58.
[24] SEMPLE J W.Immune pathophysiology of autoimmune thrombocytopenic purpura[J].Blood Rev,2002,16:9-12.
[25] GREINACHER A,WARKENTIN T E.Recognition,treatment,and prevention of heparin-induced thrombocytopenia:review and update[J].Thromb Res,200,118:165-176.
[26] VASSALLO R R,MURPHY S.A critical comparison of platelet preparation methods[J].Curr Opin Hematol,2006,13:323-330.
[27] FÜRLL B,SIETMANN R,GREINACHER A,et al.Development of a method for magnetic labeling of platelets[J].Nanomedicine,2012,8:537-544.
[28] KATHERINE A.The leak stops here:platelets as delivery vehicles for coagulation factors[J].J Clin Invest,2006,116(7):1840-1842.
[29] VLANIMIR R.Drug delivery by red blood cells:vascular carriers designed by Mother Nature[J].Expert Opin Drug Deliv,2010,7(4):403-427.
[30] 唐华非,李霞,贡联兵.红细胞载药体系研究现状[J].中国医院用药评价与分析,2011,11(10):959-960.
[31] GUTIERREZ M C,COLINO G C I,SAYALERO M M L,et al.Cell-based drug-delivery platforms[J].Ther Deliv,2012,3(1):25-41.
[32] YANN G,FRANCOISE H,ROBERT F,et al.International seminar on the red blood cells as vehicles for drugs[J].Expert Opin Biol Ther,2012,12(1):127-133.
[33] SZMILO M.Erythrocytes-the new application in medicine[J].Pol Merkur Lekarski,2013,34(199):5-8.
[34] GAMAL E I,MOHAMED F,FARS K.Characterization of human erythrocytes as potential carrier for pravastatin:an in vitro study[J].Int J Med Sci,2011,8(3) :222-230.
[35] DOMENECH C,THOMAS X,CHABAUD S,et al.L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults:results of the GRASPALL 2005-01 randomized trial[J].Br J Haematol,2011,153(1):58-65.
[36] 吴江,钱宝华,王卓,等.长春新碱载药红细胞制备及其生物学特性研究[J].第二军医大学学报,2005,26(5):551.
[37] 王宣,钱宝华,查占山,等.甲氨蝶呤与长春新碱双载红细胞的体外抗肿瘤活性研究[J].第二军医大学学报,2007,28(2):158-161.
[38] 袁盛华,汪浩,葛卫红,等.甲氨蝶呤红细胞载体对肝癌模型大鼠肝肾功能的保护作用[J].药学与临床研究,2010,18(2):164-167.
[39] 彭丽华.甲氨喋呤红细胞载体对肝癌模型大鼠肝肾功能影响观察[J].中国中医药现代远程教育,2011,11(1):149.
[40] LOTERO L A,OLMOS G,DIEZ J C.Delivery to macrophages and toxic action of etoposide carried in mouse red blood cells[J].Biochim Biophys Acta,2003,1620(1-3):160-166.
[41] MORAN N F,BAIN M D,MUQIT M M,et al.Carrier erythrocyte entrapped thymidine phosphorylase therapy for MNGI[J].Neurology,2008,71(9):686-688.
[42] HARISA G D,IBRAHIM M F,ALANAZI F K.Characterization of human erythrocytes as potential carrier for pravastatin:an in vitro study[J].Int J Med Sci,2011,8(3):222-230.
[43] YANN G,FRANCOISE H,ROBERT F,et al.International seminar on the red blood cells as vehicles for drugs[J].Expert Opin Biol Ther,2012,12(1):127-133.
[44] DREHER M R,LIU W,MICHELICH C R,et al.Tumor vascular permeability,accumulation,and penetration of macromolecular drug carriers[J].Nalt Cancer Inst,2006,98(5):335-344.
[45] 张建军,高缘,孙婉瑾.白蛋白作为药物载体的研究[J].化学进展,2011,23(8):1747-1754.
[46] 陈蕾,孙晓然,杨光,等.蛋白质载药体系的研究进展[J].现代化工,2013,33(7):46-52.
[47] BURGER A M,HARTUNG G,STEHLE G,et al.Pre-clinical evaluation of a methotrexatealbumin conjugate (MTX-HSA) in human tumor xenografts in vivo[J].Cancer,2001,95(2):718-724.
[48] 郭莉媛,平其能.多西紫杉醇白蛋白纳米粒的制备及体外评价[J].药学进展,2008,32(5):223-228.
[49] IBRAHIM N K,DESAI N,LEGHA S.et al.Phase Ⅰ and pharmacokinetic study of nanoparticle formulation of paclitaxel[J].Clin Cancer Res,2002,8(5):1038-1044.
[50] TENERIELLO M G,TSENG P C,CROZIER M,et al.Phase Ⅱ evaluation of nanopaticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian,peritoneal,or fallopian tube cancer[J].Clin Oncol,2009,27(9):1426-1431.
[51] 刘海,罗晓琴,朱亮,等.叶酸偶联白蛋白纳米粒的靶向性及药效评价[J].广东药学院院报,2007,23(1):50-52.
[52] 阚和平,刘正军,谭永法,等.抗人肝癌免疫毫微球的制备及其抗癌效果观察[J].南方医科大学学报,2008,28(8):1053-1055.
[53] HAN J,WANG Q,ZHANG Z,et al.Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer[J].Small,2014,10(3):524-535.
[54] 杨木华,杨志文,朱亮.靶向抗癌药(As2O3)白蛋白纳米球的研究[J].中华中医药学刊,2007,25(8):21-23.
[55] TAN M L,CHOONG P F M,DASS C R.Recent developments in liposomes,microparticles and nanoparticles for protein and peptide drug delivery[J].Peptides,2010,31(1):184-193.
[56] JIN H,LOVELL J F,CHEN J,et al.Mechanistic insights into LDL nanoparticle-mediated siRNA delivery[J].Bioconjugate Chem,2011,23(1):33-41.
[57] GHOSH M,SINGH A T,XU W,et al.Curcumin nanodisks:formulation and characterization[J].Nanomedicine,2011,7(2):162-167.
[58] SINGH A T,EVENS A M,ANDERSON R J,et al.All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma[J].Brit Haematol,2010,150(2):158-169.
[59] LIU C Y,WANG W,ZHOU J P,et al.Preparation and evaluation of gambogic acid loaded reconstituted high density lipoprotein nanoparticles[J].China Pharm Univ,2013,44(4):311-315.
[60] 赵腾飞,李庆勇.胆酸作为药物载体的研究进展[J].中国新药杂志,2013,22(9):1042-1046.
[61] CHONG H S,SONG H A,MA X,et al.Bile acid-based polyaminocarboxylate conjugates as targeted antitumor agents[J].Chem Commun(Camb),2009,7(21):3011-3013.
[62] LEE D Y,PARK K,KIM S K,et al.Antimetastatic effect of anorally active heparin derivative on experimentally induced metastasis[J].Clin Cancer Res,2008,14(9):2841-2849. |
